Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anna Małgorzata Czarnecka"'
Autor:
Aleksandra Sobiborowicz, Mateusz Jacek Spałek MD, PhD, Anna Małgorzata Czarnecka MD, PhD, MSc, Piotr Rutkowski MD, PhD
Publikováno v:
Cancer Control, Vol 28 (2021)
Background: There is currently no consensus on optimal management of patients with primary or recurrent non-resectable/residual retroperitoneal sarcomas (RPS). The objective of this study was to document the outcomes of patients with primary or recur
Externí odkaz:
https://doaj.org/article/0076947b1d1f46e1ae924a5d0b000ac2
Autor:
Mateusz Jacek Spałek, Jan Poleszczuk, Anna Małgorzata Czarnecka, Monika Dudzisz-Śledź, Aleksandra Napieralska, Jacek Matysiakiewicz, Marzanna Chojnacka, Anna Raciborska, Aleksandra Sztuder, Adam Maciejczyk, Agata Szulc, Tomasz Skóra, Bożena Cybulska-Stopa, Tomasz Winiecki, Joanna Kaźmierska, Bartłomiej Tomasik, Jacek Fijuth, Piotr Rutkowski
Publikováno v:
Cells, Vol 10, Iss 2, p 366 (2021)
Background: Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors
Externí odkaz:
https://doaj.org/article/4cec9d18cb304c4a89fb071ca37c291a
Autor:
Bożena Cybulska-Stopa, Karolina Piejko, Krzysztof Ostaszewski, Robert Dziura, Łukasz Galus, Barbara Ziółkowska, Natasza Kempa-Kamińska, Marcin Ziętek, Wiesław Bal, Agnieszka Kamycka, Monika Dudzisz-Śledź, Tomasz Kubiatowski, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz, Anna Małgorzata Czarnecka, Piotr Rutkowski
Publikováno v:
Melanoma Research. 33:208-217
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd933660d18348df171d3869f953f4f
https://doi.org/10.1097/cmr.0000000000000885
https://doi.org/10.1097/cmr.0000000000000885
Autor:
Anna Małgorzata Czarnecka, Paweł Sobczuk, Paweł Rogala, Tomasz Świtaj, Joanna Placzke, Katarzyna Kozak, Anna Mariuk-Jarema, Mateusz Spałek, Monika Dudzisz-Śledź, Paweł Teterycz, Aneta Borkowska, Piotr Rutkowski
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(8)
Immunotherapy (ITH) holds the possibility of tumor burden decrease after initial RECIST 1.1 defined progression. The clinical concept of treating selected patients (pts) beyond disease progression (PD) is supported by so-called pseudoprogression phen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a616ea0bf78912e7829a3e9bfdc5b7
https://pubmed.ncbi.nlm.nih.gov/35075516
https://pubmed.ncbi.nlm.nih.gov/35075516
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Renal cell carcinoma (RCC) drug resistance mechanisms still remain elusive. Although most patients initially respond to targeted therapy (i.e. to tyrosine kinase inhibitors), acquired resistance can still eventually develop. Most of the patients suff
Externí odkaz:
https://doaj.org/article/aedb738a3dc24343a2bebb75a320c767